Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Recently, clinical trial data showed that rapid attainment of goal blood pressure (BP) reduces the risk for cardiovascular disease (CVD) events. It is unknown whether patient characteristics linked to the magnitude of CVD risk influence the speed of BP control. Time to attain goal systolic BP (SBP) in Kaplan-Meier survival curves was contrasted for strata of baseline characteristics and intensity of hypertension treatment. Survival analyses showed that albuminuria, diabetes, increased body mass index, millimeters of mercury above Joint National Committee (JNC) SBP goal, higher Framingham risk score, older age, depressed estimated glomerular filtration rate, and greater intensity of antihypertensive drug treatment all predicted slower JNC SBP goal attainment (P < 0.015); the intensity of antihypertensive drug therapy when goal BP was attained was also greater in all conditions linked to slow goal attainment. Cox proportional hazards model that included the above patient characteristics revealed all characteristics slowed attainment of JNC SBP goals (P < 0.03). Thus, patient characteristics influence speed of BP control and practitioners should avoid therapeutic inertia.
- Fields, L.E., Burt, V.L., Cutler, J.A. (2004) The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 44: pp. 398-404 CrossRef
- Knight, E.L., Bohn, R.L., Wang, P.S. (2001) Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 38: pp. 809-814 CrossRef
- Munrow, P.J. (1998) Detection and control of hypertension in the population: the United States experience. Am J Hypertens 11: pp. 744-746 CrossRef
- Yusuf, S., Sleight, P., Pogue, J. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: pp. 145-153 CrossRef
- Cushman, W.C., Ford, C.E., Cutler, J.A. (2002) Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 4: pp. 393-404 CrossRef
- Julius, S., Kjeldsen, S.E., Weber, M. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: pp. 2022-2031 CrossRef
- Staessen, J.A., Thijisq, L., Fagard, R. (2004) Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 22: pp. 847-857 CrossRef
- Sutton Tyrrell, K., Wildman, R., Newman, A., Kuller, L.H. (2003) Extent of cardiovascular risk reduction associated with treatment of isolated systolic hypertension. Arch Intern Med 163: pp. 2728-2731 CrossRef
- Basile, J.N., Chrysant, S. (2006) The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 20: pp. 169-175 CrossRef
- Papademetriou, V., Farsang, C., Elmfeldt, D. (2004) Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 44: pp. 1175-1180
- Dahlof, B., Sever, P.S., Poulter, N.R. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366: pp. 895-906 CrossRef
- Budtz-Jorgensen, E., Keiding, N., Grandjean, P., Weihe, P. (2007) Confounder selection in environmental epidemiology: assessment of health effects of prenatal mercury exposure. Ann Epidemiol 17: pp. 27-35 CrossRef
- Okonofua, E.C., Simpson, K.N., Jesri, A. (2006) Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 47: pp. 345-351 CrossRef
- Andrade, S.E., Gurwitz, J.H., Field, T.S. (2004) Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care 10: pp. 481-486
- O’Connor, P.J. (2003) Overcome clinical inertia to control systolic blood pressure. Arch Intern Med 163: pp. 2677-2678 CrossRef
- Flack, J.M., Gardin, J.M., Yunis, C., Liu, K. (1999) Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: the CARDIA study. Am Heart J 138: pp. 856-864 CrossRef
- Staessen, J.A., Li, Y., Thijs, L., Wang, J.G. (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 28: pp. 385-407 CrossRef
- Flack, J.M., Neaton, J., Grimm, R. (1995) Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 92: pp. 2437-2745
- The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [no authors listed]. Arch Intern Med 1997, 157:2413–2446.
- Chobanian, A.V., Bakris, G.L., Black, H.R. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: pp. 2560-2572 CrossRef
- Talbert, R.L. (2002) New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III. Am J Manag Care 8: pp. S301-S307
- Carlini, R., Obialo, C.I., Rothstein, M. (1993) Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6: pp. 103-107
- Douglas, J.G., Bakris, G.L., Epstein, M. (2003) Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 163: pp. 525-541 CrossRef
- Flack, J.M., Yunis, C., Preisser, J. (2000) The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group. Arch Intern Med 160: pp. 1842-1847 CrossRef
- Berlowitz, D.R., Ash, A.S., Hickey, E.C. (1998) Inadequate management of blood pressure in a hypertensive population. N Engl J Med 339: pp. 1957-1963 CrossRef
- Hicks, L.S., Fairchild, D.G., Horng, M.S. (2004) Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension 44: pp. 429-434 CrossRef
- Weber, M.A., Julius, S., Kjeldsen, S.E. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363: pp. 2049-2051 CrossRef
- Does earlier attainment of blood pressure goal translate into fewer cardiovascular events?
Current Hypertension Reports
Volume 10, Issue 5 , pp 398-404
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors